Effect of sodium–glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims‐based cohort study

Documents similaires

• Effect of sodium–glucose cotransporter 2 inhibitors on serum low‐density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus
  par: Tasuku Imada, et autres
  Publié: (2024)
• Clinical use and monitoring of adverse effects of sodium‐glucose cotransporter‐2 inhibitors in persons with type 1 diabetes mellitus
  par: Chinatsu Sakai, et autres
  Publié: (2025)
• The impact of dynamic kidney function prior to using sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes patients with low‐risk renal disease progression
  par: Yen‐Chen Chiu, et autres
  Publié: (2025)
• Effect of administration and withdrawal of the sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on renal protection in individuals with type 2 diabetes mellitus and diabetic nephropathy: A multicenter, single‐arm study (RESTORE‐nephropathy study)
  par: Ayako Shigeta, et autres
  Publié: (2025)
• Comment on “The impact of dynamic kidney function prior to using sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes patients with low‐risk renal disease progression”
  par: Shyam Sundar Sah, et autres
  Publié: (2025)